January 26, 2022
We are proud to share the Sarah Cannon Transplant & Cellular Therapy Program at Research Medical Center has received accreditation through the Foundation for the Accreditation of Cellular Therapy (FACT).
This FACT accreditation places us in the highest level of transplant programs and assures our services meet the most rigorous standards of blood and marrow transplant.
FACT accredited programs uphold and retain the confidence of medical professionals, third-party payers and regulators in the quality of the organization’s cellular therapy services and provides our patients with the highest quality care available.
“We could not be more pleased to achieve FACT accreditation for our adult autologous transplant and cellular therapy program,” says Suman Kambhampati, MD, program site director. “Our program is proud to provide those facing blood cancer with the highest level of blood and marrow transplantation in addition to our complex blood cancer care.”
The blood cancer program at Research Medical Center has provided patients with blood cancers such as leukemia, lymphoma and myeloma convenient, community-based access to complex blood cancer care, including clinical trials and innovative therapies for more than six years. The transplant and cellular therapy program was established in 2019 and provides adult autologous transplant services, which use a patient’s own stem cells during the transplant process.
The Sarah Cannon Transplant & Cellular Therapy Program at Research Medical Center, which includes a dedicated inpatient unit and outpatient clinic staffed by a multidisciplinary care team, is part of the Sarah Cannon Transplant & Cellular Therapy Network, which brings together physician-led blood cancer programs across the United States and United Kingdom and is one of the largest providers of transplant and cellular therapies in the world. In fact, it conducts approximately 1,200 transplants annually through nine FACT/JACIE accredited transplant centers and has performed more than 16,000 transplants since the inception of its first program.
“We thoughtfully assembled a local team of experts to meet the needs of our community’s patients before, during and after transplant. Our wider collaboration with our colleagues in the Sarah Cannon network allows us to leverage our shared knowledge, experience and capabilities in an effort to bring the most innovative and highest quality of care to our patients,” explains Joseph Restivo, DO, medical director of Transfusion Medicine and Cellular Therapy Collections, Sarah Cannon Cancer Institute at HCA Midwest Health.
“The Sarah Cannon Transplant and Cellular Therapy Program at Research Medical Center is committed to providing an unparalleled experience for patients seeking treatment for blood cancer,” says Frank Slovick, MD, co-medical director. “These patients have very unique needs, requiring care from a highly specialized team. Our inclusion in the Sarah Cannon Transplant & Cellular Therapy Network not only assures access to new therapies through major clinical trials for our patients, but now the opportunity to offer a comprehensive and high-quality transplant and cellular therapy service with FACT accreditation.”
“Achieving FACT accreditation assures patients, care givers, physicians and the community at large of high quality cellular and transplant therapies,” shares Carlos Bachier, MD, program director. “The transplant and cellular therapy program at Research Medical Center assembled an outstanding team of nurses, providers, pharmacists, coordinators and other staff who are providing the best possible care and cutting-edge cellular therapies to patients in our region.”
“Research Medical Center is pleased to offer patients in the region the quality and expertise of the Sarah Cannon Transplant & Cellular Therapy Network including blood and marrow transplants,” says Ashley McClellan, chief executive officer, Research Medical Center. “We strive to give our patients the highest quality and most comprehensive services available for complex blood disorders. Our FACT accredited adult autologous program exemplifies that commitment and expands the treatment options available to people living with blood cancer.”